EU agency backs new Roche, Astellas, Sanofi, Vivus drugs
LONDON, April 26
LONDON, April 26 (Reuters) - European regulators have recommended approval of two new cancer drugs, called Erivedge and Xtandi, from Roche and Astellas.
The European Medicines Agency said on Friday its experts had also backed MAC1, a tissue-engineered medicine for cartilage defects from Sanofi, and Spedra, a new erectile dysfunction drug from Vivus.
Recommendations for marketing approval by the EMA's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.
- Police seek motive in fatal Washington state school shooting
- U.S. nurse quarantined over Ebola criticizes her treatment |
- Washington state teen shooter's family living in 'nightmare'
- Two deputies killed, two others hurt in California shooting spree
- Wall St. finally turning on Amazon as Bezos magic fades